RBC Capital raised the firm’s price target on Encompass Health to $70 from $66 and keeps an Outperform rating on the shares. The company’s Q1 earnings marked a "strong" result to start 2023, and its impressive discharge growth is demonstrating the management’s commitment to meeting demand and taking share in its markets, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EHC:
- Encompass Health price target raised to $73 from $70 at Deutsche Bank
- Encompass Health price target raised to $74 from $69 at Mizuho
- Encompass Health price target raised to $74 from $69 at BofA
- Encompass Health raises 2023 adjusted EPs view to $2.94-$3.23 from $2.87-$3.16
- Encompass Health reports Q1 adjusted EPS 88c, consensus 70c
